Kura Oncology, Inc.

( )
KURA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.57%283.291.5%$876.09m
GILDGilead Sciences, Inc. -0.02%87.961.0%$686.29m
MRNAModerna, Inc. -1.36%173.540.0%$642.89m
REGNRegeneron Pharmaceuticals, Inc. -1.06%747.472.6%$489.87m
VRTXVertex Pharmaceuticals, Inc. -1.82%311.811.9%$475.10m
BIIBBiogen, Inc. -0.44%291.471.8%$409.07m
ILMNIllumina, Inc. -3.69%205.983.2%$225.66m
BMRNBioMarin Pharmaceutical, Inc. -1.27%102.224.2%$161.73m
BNTXBioNTech SE -3.05%161.620.0%$160.60m
AXSMAxsome Therapeutics, Inc. -2.63%75.261.6%$141.48m
SNSSSunesis Pharmaceuticals, Inc. -6.51%2.010.7%$140.51m
MRTXMirati Therapeutics, Inc. -22.89%71.521.6%$125.68m
HALOHalozyme Therapeutics, Inc. 0.79%56.3818.4%$81.14m
NVAXNovavax, Inc. -4.71%16.7875.3%$80.38m
IMGOImago BioSciences, Inc. 0.00%35.860.0%$59.53m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.